Medicare Enrolled
Dr. Raphael Kieval, MD
Rheumatology · Brockton, MA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Speaking/Promotional
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Kieval from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Kieval?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Kieval
Dr. Raphael Kieval is a rheumatology specialist in Brockton, MA, with 20 years of NPI registration. Based on federal Medicare data, Dr. Kieval performed 143,339 Medicare services across 1,851 unique beneficiaries.
Between the years covered by Open Payments, Dr. Kieval received a total of $122,438 from 57 pharmaceutical and/or device companies across 1781 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in rheumatology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Kieval is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ Top 1% volume in MA
$122,438 industry payments
Medicare Practice Summary
Medicare Utilization ↗143,339
Medicare services
Top 1% in MA for rheumatology
1,851
Unique beneficiaries
$11
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~7,167 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Tocilizumab injection (Actemra) | 43,675 | $5 | $7 |
| Certolizumab injection (Cimzia) An injection of certolizumab pegol administered under the direct supervision of a physician. |
33,200 | $4 | $11 |
| Golimumab infusion (Simponi Aria) Administration of golimumab medication directly into a vein. This code specifies the dosage amount of 1 milligram for intravenous delivery. |
21,100 | $10 | $27 |
| Romosozumab injection (Evenity) for osteoporosis | 15,541 | $8 | $12 |
| Denosumab injection (Prolia/Xgeva) | 13,860 | $18 | $25 |
| Abatacept infusion (Orencia) An injection of abatacept administered under the direct supervision of a physician. This code is used for Medicare when the drug is not self-administered. |
9,325 | $34 | $71 |
| Rituximab injection, 10 mg Administration of a 10 mg dose of rituximab medication via injection. |
2,800 | $63 | $123 |
| Normal saline infusion, 250 cc Administration of 250 cubic centimeters of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater fluid. |
921 | $0 | $1 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
635 | $93 | $270 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
619 | $63 | $184 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
553 | $57 | $188 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
442 | $108 | $345 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
167 | $23 | $110 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
120 | $6 | $14 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
71 | $120 | $415 |
| Betamethasone steroid injection An injection containing a combination of betamethasone acetate and betamethasone sodium phosphate. |
54 | $4 | $12 |
| Joint injection, major joint Removal of fluid from a large joint and/or injection of medication into the joint space. |
37 | $47 | $175 |
| Tendon or ligament injection A procedure involving the injection of medication into a tendon or ligament. |
36 | $33 | $150 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
31 | $22 | $70 |
| Methylprednisolone injection, up to 125 mg An injection of methylprednisolone sodium succinate, a corticosteroid medication, with a dosage of up to 125 mg. |
30 | $4 | $60 |
| New patient office visit (30-44 min) An initial office visit for a new patient lasting between 30 and 44 minutes. This code is used when the total time spent on the date of the encounter falls within this range. |
27 | $77 | $273 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
25 | $50 | $263 |
| Methylprednisolone acetate injection, 80 mg An injection of 80 mg of methylprednisolone acetate, a corticosteroid medication. |
23 | $7 | $40 |
| Joint fluid aspiration or injection, small joint Removal of fluid from a small joint or injection of medication into a small joint. |
18 | $31 | $135 |
| Injection, methylprednisolone acetate, 40 mg | 15 | $6 | $30 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
14 | $122 | $364 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
22.2% high complexity
76.8% medium
1.0% routine
Industry Payment Transparency
Open Payments through 2024 ↗$122,438
Total received (2018-2024)
Avg $17,491/year across 7 years
Top 5% in MA for rheumatology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
57
Companies
1,781
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$99,972 (81.7%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$22,466 (18.3%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$29,446
2023
$36,909
2022
$20,890
2021
$4,102
2020
$5,019
2019
$16,472
2018
$9,600
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Janssen Biotech, Inc.
$13,895
ABBVIE INC.
$12,250
Amgen Inc.
$635
UCB, Inc.
$400
Novartis Pharmaceuticals Corporation
$359
AstraZeneca Pharmaceuticals LP
$271
PFIZER INC.
$270
Sandoz Inc.
$211
Mallinckrodt Hospital Products Inc.
$160
Lilly USA, LLC
$160
E.R. Squibb & Sons, L.L.C.
$103
ANI Pharmaceuticals, Inc.
$94
Alexion Pharmaceuticals, Inc.
$94
Fresenius Kabi USA, LLC
$93
GENZYME CORPORATION
$90
Boehringer Ingelheim Pharmaceuticals, Inc.
$78
Organon Llc
$76
Janssen Scientific Affairs, LLC
$60
GlaxoSmithKline, LLC.
$46
Kyowa Kirin, Inc.
$44
Kiniksa Pharmaceuticals International, plc
$31
SOBI, INC
$27
Top 3 companies account for 90.9% of 2024 payments
All-time payments by company (2018-2024) ›
ABBVIE INC.
$42,069
Janssen Biotech, Inc.
$38,330
AbbVie, Inc.
$19,852
AbbVie Inc.
$3,262
Amgen Inc.
$2,953
PFIZER INC.
$1,728
Lilly USA, LLC
$1,661
UCB, Inc.
$1,611
Novartis Pharmaceuticals Corporation
$1,600
Janssen Scientific Affairs, LLC
$1,160
GlaxoSmithKline, LLC.
$892
AstraZeneca Pharmaceuticals LP
$736
E.R. Squibb & Sons, L.L.C.
$722
Mallinckrodt Hospital Products Inc.
$562
Horizon Therapeutics plc
$550
Celgene Corporation
$521
Regeneron Healthcare Solutions, Inc.
$512
Genentech USA, Inc.
$461
Boehringer Ingelheim Pharmaceuticals, Inc.
$320
Hikma Pharmaceuticals USA
$311
GENZYME CORPORATION
$307
ANI Pharmaceuticals, Inc.
$246
Sandoz Inc.
$232
Alexion Pharmaceuticals, Inc.
$197
Radius Health, Inc.
$192
Fresenius Kabi USA, LLC
$155
Aurinia Pharma U.S., Inc.
$119
Takeda Pharmaceuticals U.S.A., Inc.
$81
SOBI, INC
$78
Organon LLC
$78
Organon Llc
$76
SANOFI-AVENTIS U.S. LLC
$75
Merck Sharp & Dohme Corporation
$71
Kiniksa Pharmaceuticals, Ltd.
$64
West-Ward Pharmaceuticals
$62
Sobi, Inc
$54
Exeltis, USA Inc.
$54
Bioventus LLC
$47
Pacira Pharmaceuticals Incorporated
$45
Kyowa Kirin, Inc.
$44
TerSera Therapeutics LLC
$41
Kiniksa Pharmaceuticals International, plc
$31
Kowa Pharmaceuticals America, Inc.
$30
Zimmer Biomet Holdings, Inc.
$28
Purdue Pharma L.P.
$27
Celltrion USA Inc.
$23
Antares Pharma, Inc.
$20
RedHill Biopharma Inc.
$20
Ultragenyx Pharmaceutical Inc.
$19
Flexion Therapeutics, Inc.
$18
Neuronetics, Inc.
$16
Ironwood Pharmaceuticals, Inc
$14
MEDEXUS PHARMA, INC.
$14
Horizon Pharma plc
$12
MEDAC PHARMA, INC.
$12
Mallinckrodt Enterprises LLC
$11
Gilead Sciences, Inc.
$11
Top 3 companies account for 81.9% of all-time payments
Associated products mentioned in payments ›
ACTHAR · AMJEVITA · Actemra · Arcalyst · BENLYSTA · Bimzelx · COLOGUARD DNA CAPTURE REAGENTS · COSENTYX · CYLTEZO · Cimzia · Crysvita · DUZALLO · Durolane · EVENITY · EVUSHELD · Enbrel · FLUMIST · FORTEO · Gel One · HADLIMA · HUMIRA · HYRIMOZ · Humira · IDACIO · ILARIS · INFLECTRA · KEVZARA · KEVZARA SARILUMAB INJECTION · KINERET · KRYSTEXXA · Kineret · LUPKYNIS · LYRICA · Mitigare · Movantik · NEUROSTAR TMS THERAPY · NUCALA · OCTAGAM IMMUNE GLOBULIN (HUMAN) · OFEV · OLUMIANT · ORENCIA · Otezla · Otrexup · PREVNAR - 13 · PREVNAR 20 · PURIFIED CORTROPHIN GEL · Prolia · QMIIZ ODT · REMICADE · RENFLEXIS · RINVOQ · Rasuvo · Rinvoq · Rituxan · SAPHNELO · SEGLENTIS · SIMPONI · SIMPONI ARIA · SKYRIZI · STELARA · STRENSIQ · SYMPROIC · Seglentis · Strensiq · TALTZ · TAVNEOS · TREMFYA · Tymlos · ULTOMIRIS · Uloric · XELJANZ · YUFLYMA · Zilretta
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (82%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in rheumatology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 5% for rheumatology in MA.
Geographic Context
Rheumatologists within 10 mi
152
Per 100K population
28.6
County median income
$109,698
Nearest hospital
GOOD SAMARITAN MEDICAL CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Kieval is a mixed practice specialist, with above-average Medicare volume (top 1% in MA), with speaking/promotional industry engagement in the top 5% of MA peers, with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Kieval experienced with tocilizumab injection (actemra)?
Based on Medicare claims data, Dr. Kieval performed 43,675 tocilizumab injection (actemra) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Kieval receive payments from pharmaceutical companies?
Yes. Dr. Kieval received a total of $122,438 from 57 companies across 1,781 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Kieval's costs compare to other rheumatologists in Brockton?
Dr. Kieval's average Medicare payment per service is $11. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Kieval) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Rheumatologists in Brockton
Browse rheumatologists in Brockton ranked by procedure volume and transparency data.
Highest volume
Top Rheumatologists in MA
Rheumatologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Rheumatologists in MA
Which MA rheumatologists receive the most from drug and device companies.
By company
ABBVIE INC. Payments to Doctors
See all physicians who received payments from ABBVIE INC.
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc.
By company
AbbVie, Inc. Payments to Doctors
See all physicians who received payments from AbbVie, Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology